Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Molecular Characterization of Chemoresistant Cell Populations Improves Risk Stratification and Therapy Response Prediction in Pediatric AML

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE271137 | GEO | 2025/11/26

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Molecular Characterization of Chemoresistant Cell Populations Improves Risk Stratification and Therapy Response Prediction in Pediatric AML [Treatment_Study_RNA-seq]

Project description:Most pediatric acute myeloid leukemia (pAML) patients achieve complete remission after chemotherapy. However, relapse remains common, and nearly 40% ultimately die of the disease. Prognosis is guided by cytogenetic biomarkers and measurable residual disease (MRD) after one chemotherapy cycle, at which point the highest-risk patients are referred to targeted experimental therapies and stem cell transplantation (SCT). Because these therapies are most effective before relapse, accurate early risk prediction is essential for improving outcomes. To address help this need, we analyzed paired diagnosis–relapse samples from 33 pAML patients at single-cell resolution and identified chemoresistant pAML populations whose abundance at diagnosis significantly improved risk prediction. Incorporation of these populations into a risk model uncovered a previously unrecognized subgroup—representing 20% of pAML cases—with event-free survival (EFS) below 40%, accounting for half of the deaths among patients that were not prescribed SCT after a cycle of chemotherapy. Furthermore, molecular characterization of these chemoresistant populations revealed therapeutic targets and targeted interventions relevant to most high-risk patients, paving the way for more effective treatments for high risk pAML patients.

2025-11-26 | GSE308825 | GEO

Molecular Characterization of Chemoresistant Cell Populations Improves Risk Stratification and Therapy Response Prediction in Pediatric AML [pAML PDX scRNA-seq]

2025-11-26 | GSE271136 | GEO

Molecular Characterization of Chemoresistant Cell Populations Improves Risk Stratification and Therapy Response Prediction in Pediatric AML [pAML Patients scRNA-seq]

2025-11-26 | GSE270894 | GEO

Molecular Characterization of Chemoresistant Cell Populations Improves Risk Stratification and Therapy Response Prediction in Pediatric AML [pAML PDX Bulk RNA-seq]

2025-11-26 | GSE271134 | GEO

Molecular Characterization of Chemoresistant Cell Populations Improves Risk Stratification and Therapy Response Prediction in Pediatric AML [pAML Patients Bulk RNA-seq]

2025-11-26 | GSE270892 | GEO

Molecular Characterization of Chemoresistant Cell Populations Improves Risk Stratification and Therapy Response Prediction in Pediatric AML

Project description:Molecular Characterization of Chemoresistant Cell Populations Improves Risk Stratification and Therapy Response Prediction in Pediatric AML

| PRJNA1130038 | ENA

Molecular Characterization of Chemoresistant Cell Populations Improves Risk Stratification and Therapy Response Prediction in Pediatric AML [Treatment_Study_RNA-seq]

Project description:Molecular Characterization of Chemoresistant Cell Populations Improves Risk Stratification and Therapy Response Prediction in Pediatric AML [Treatment_Study_RNA-seq]

| PRJNA1332760 | ENA

Molecular Characterization of Chemoresistant Cell Populations Improves Risk Stratification and Therapy Response Prediction in Pediatric AML [pAML Patients scRNA-seq]

Project description:Molecular Characterization of Chemoresistant Cell Populations Improves Risk Stratification and Therapy Response Prediction in Pediatric AML [pAML Patients scRNA-seq]

| PRJNA1128710 | ENA

Molecular Characterization of Chemoresistant Cell Populations Improves Risk Stratification and Therapy Response Prediction in Pediatric AML [pAML PDX scRNA-seq]

Project description:Molecular Characterization of Chemoresistant Cell Populations Improves Risk Stratification and Therapy Response Prediction in Pediatric AML [pAML PDX scRNA-seq]

| PRJNA1130037 | ENA

Molecular Characterization of Chemoresistant Cell Populations Improves Risk Stratification and Therapy Response Prediction in Pediatric AML [pAML PDX Bulk RNA-seq]

Project description:Molecular Characterization of Chemoresistant Cell Populations Improves Risk Stratification and Therapy Response Prediction in Pediatric AML [pAML PDX Bulk RNA-seq]

| PRJNA1130035 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data